<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100476</url>
  </required_header>
  <id_info>
    <org_study_id>2010 - M5</org_study_id>
    <nct_id>NCT01100476</nct_id>
  </id_info>
  <brief_title>Mynx M5 One Hour Ambulation Study</brief_title>
  <acronym>Mynx</acronym>
  <official_title>Single-center, Post Market, Prospective, Consecutive, Single-arm Study Compared to Historical Control (Diagnostic Arm of the Mynx 6/7F Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Associates of the Delaware Valley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AccessClosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiovascular Associates of the Delaware Valley</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Mynx Vascular Closure Device (Mynx M5) is a sponge-like material used to close the hole
      in the artery after patients undergo a diagnostic endovascular procedures
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Key Inclusion:

        1. Patients &gt;18 yrs of age

        2. Patient underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath
           via the common femoral artery.

        3. Patient is able to ambulate (routinely walk 6 meters or 20 feet without assistance for
           any reason) as assessed by investigator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; Tolerability</measure>
    <time_frame>Enrollment approx for 4 months</time_frame>
    <description>To assess safety and tolerability of participants ambulating within one hour of placement of the Mynx M5 Closure Device. Participants will be assessed for adverse event occurrence for 30 +/-7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>30 +/- 7days</time_frame>
    <description>Assess device success, time to dischargeability, major and minor complications in all patients enrolled in the study</description>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Angiography</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular Diagnostic Procedures</intervention_name>
    <description>Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery</description>
    <other_name>Angiography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt; 18 years of age

          -  Patient underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath
             in the common femoral artery

          -  Patient has been informed and understands the nature of the study and provides written
             INformed COnsent approved by the appropriate Institutional Review Board (IRB) prior to
             enrollment

          -  Patient is able to ambulate (routinely walk 6 meters or 20 feet without assistance for
             any reason) as assessed by the investigator

        Exclusion Criteria:

        Pre-Procedure Exclusion Criteria

          -  Patient had a prior surgical procedure, PTA, stent placement, or vascular graft in the
             common femoral artery

          -  Patient has a bleeding disorder such as thrombocytopenia

          -  Patient has uncontrolled hypertension

          -  Patient is morbidly obese (BMI &gt;40 kg/m2

          -  Patient is pregnant or lactating

          -  Patient has a documented INR &gt;1.5 or patients currently receiving glycoprotein
             IIb/IIIa platelet inhibitor

          -  Patient has a known severe allergy to contrast medium

          -  Patient has a known allergy to PEG

          -  Patient is unable to ambulate at one hour secondary to a co-morbid condition

          -  Patient is know to require an extended hospitalization or re-hospitalization
             (e.g.patient is undergoing coronary artery bypass graft (CABG) surgery) or patient is
             scheduled to have a CABG surgery &lt;30 days following the procedure

        Intra-Procedure Exclusion Criteria

          -  Common femoral artery is &lt;5mm in diameter

          -  Patient with clinically significant peripheral vascular disease in the vicinity of the
             puncture

          -  Puncture site is located above the most inferior border of the inferior epigastric
             artery (IEA) and/or above the inguinal ligament based upon bony landmarks

          -  Patient has a posterior puncture or multiple punctures in an attempt to gain access

          -  Patient has an ipsilateral venous sheath

          -  Patient has a pre-existing arterial bleed/extravasation identified on pre-procedure
             femoral arteriogram, hematoma, pseudoaneurysm or arteriovenous fistula present prior
             to sheath removal

          -  Patient has intra-procedural bleeding around the access site prior to sheath removal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay K Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Associates of the Delaware Valley</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary F Kinder, RN, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Cardiovascular Associates of the Delaware Valley</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiovascular Associates of the Delaware Valley</investigator_affiliation>
    <investigator_full_name>Vijayendra K. Verma, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Closure Device</keyword>
  <keyword>endovascular procedures</keyword>
  <keyword>sealing femoral arterial access</keyword>
  <keyword>Mynx M5</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

